$1.4 Billion is the total value of EcoR1 Capital, LLC's 50 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 77.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XNCR | XENCOR INC | $176,381,000 | +19.8% | 4,547,072 | 0.0% | 12.58% | +15.6% | |
| KURA | KURA ONCOLOGY INC | $141,205,000 | +88.0% | 4,608,529 | 0.0% | 10.07% | +81.5% | |
| RLAY | New | RELAY THERAPEUTICS INC | $136,316,000 | – | 3,200,649 | +100.0% | 9.72% | – |
| PRTA | PROTHENA CORP PLC | $94,172,000 | -4.5% | 9,426,640 | 0.0% | 6.72% | -7.8% | |
| MORF | Buy | MORPHIC HLDG INC | $77,642,000 | +1.1% | 2,839,884 | +0.1% | 5.54% | -2.3% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $77,097,000 | +88.7% | 464,298 | +29.7% | 5.50% | +82.2% |
| ORIC | ORIC PHARMACEUTICALS INC | $66,082,000 | -25.9% | 2,642,218 | 0.0% | 4.71% | -28.4% | |
| RNA | AVIDITY BIOSCIENCES INC | $59,226,000 | -0.4% | 2,103,950 | 0.0% | 4.22% | -3.8% | |
| ANAB | Buy | ANAPTYSBIO INC | $47,544,000 | -30.8% | 3,223,324 | +4.8% | 3.39% | -33.2% |
| NLTX | Buy | NEOLEUKIN THERAPEUTICS INC | $46,355,000 | -21.0% | 3,862,931 | +9.2% | 3.30% | -23.8% |
| AKUS | AKOUOS INC | $45,191,000 | +1.6% | 1,975,984 | 0.0% | 3.22% | -1.9% | |
| ASMB | Sell | ASSEMBLY BIOSCIENCES INC | $41,895,000 | -43.0% | 2,548,382 | -19.2% | 2.99% | -45.0% |
| NRIX | New | NURIX THERAPEUTICS INC | $41,618,000 | – | 1,192,156 | +100.0% | 2.97% | – |
| AMTI | APPLIED MOLECULAR TRANS INC | $36,593,000 | +26.6% | 1,150,000 | 0.0% | 2.61% | +22.2% | |
| BCEL | Buy | ATRECA INC | $33,901,000 | +7.0% | 2,426,685 | +63.0% | 2.42% | +3.3% |
| GERN | GERON CORP | $33,462,000 | -20.2% | 19,230,769 | 0.0% | 2.39% | -22.9% | |
| STRO | Buy | SUTRO BIOPHARMA INC | $31,292,000 | +120.5% | 3,113,617 | +70.3% | 2.23% | +112.9% |
| RCUS | ARCUS BIOSCIENCES INC | $31,023,000 | -30.7% | 1,810,000 | 0.0% | 2.21% | -33.1% | |
| New | GOSSAMER BIO INCnote | $31,008,000 | – | 30,000,000 | +100.0% | 2.21% | – | |
| SURF | Sell | SURFACE ONCOLOGY INC | $22,999,000 | -30.4% | 3,333,177 | -33.8% | 1.64% | -32.8% |
| CYCN | CYCLERION THERAPEUTICS INC | $16,673,000 | +2.9% | 2,742,276 | 0.0% | 1.19% | -0.7% | |
| ALVR | New | ALLOVIR INC | $12,293,000 | – | 447,012 | +100.0% | 0.88% | – |
| GLYC | Buy | GLYCOMIMETICS INC | $11,436,000 | +61.0% | 3,725,150 | +97.2% | 0.82% | +55.2% |
| BCTG | New | BCTG ACQUISITION CORP | $8,288,000 | – | 800,000 | +100.0% | 0.59% | – |
| CNST | CONSTELLATION PHARMCETICLS Icall | $8,104,000 | -32.6% | 400,000 | 0.0% | 0.58% | -34.9% | |
| LSAC | New | LIFESCI ACQUISITION CORP*w exp 02/14/202 | $7,818,000 | – | 630,505 | +100.0% | 0.56% | – |
| ALPN | New | ALPINE IMMUNE SCIENCES INC | $6,516,000 | – | 741,290 | +100.0% | 0.46% | – |
| ITOS | New | ITEOS THERAPEUTICS INC | $6,414,000 | – | 260,000 | +100.0% | 0.46% | – |
| DFHTU | New | DEERFIELD HEALTHCARE TECH ACunit 07/16/2025 | $5,315,000 | – | 500,000 | +100.0% | 0.38% | – |
| PANAU | New | PANACEA ACQUISITION CORPunit 99/99/9999 | $4,680,000 | – | 390,000 | +100.0% | 0.33% | – |
| IRWD | IRONWOOD PHARMACEUTICALS INCcall | $4,498,000 | -12.8% | 500,000 | 0.0% | 0.32% | -15.7% | |
| HSAQ | New | HEALTH SCIENCES ACQ CORP 2 | $4,400,000 | – | 400,000 | +100.0% | 0.31% | – |
| DYN | New | DYNE THERAPEUTICS INC | $4,341,000 | – | 215,000 | +100.0% | 0.31% | – |
| ACRS | ACLARIS THERAPEUTICS INC | $3,935,000 | +58.6% | 1,531,312 | 0.0% | 0.28% | +53.6% | |
| FSDC | New | FS DEV CORP | $3,919,000 | – | 350,000 | +100.0% | 0.28% | – |
| MTCR | New | METACRINE INC | $3,403,000 | – | 333,332 | +100.0% | 0.24% | – |
| KYMR | New | KYMERA THERAPEUTICS INC | $3,231,000 | – | 100,000 | +100.0% | 0.23% | – |
| GLYC | New | GLYCOMIMETICS INCcall | $2,610,000 | – | 850,000 | +100.0% | 0.19% | – |
| RPRX | ROYALTY PHARMA PLC | $2,104,000 | -13.3% | 50,000 | 0.0% | 0.15% | -16.2% | |
| XCUR | Sell | EXICURE INC | $1,781,000 | -56.4% | 1,017,801 | -39.2% | 0.13% | -57.9% |
| FPRX | FIVE PRIME THERAPEUTICS INC | $1,786,000 | -23.0% | 379,945 | 0.0% | 0.13% | -25.7% | |
| PMVP | New | PMV PHARMACEUTICALS INC | $1,775,000 | – | 50,000 | +100.0% | 0.13% | – |
| RPTX | REPARE THERAPEUTICS INC | $1,539,000 | -0.8% | 50,000 | 0.0% | 0.11% | -4.3% | |
| MGTX | MEIRAGTX HLDGS PLC | $1,255,000 | +5.7% | 94,819 | 0.0% | 0.09% | +1.1% | |
| ICPT | INTERCEPT PHARMACEUTICALS INcall | $1,049,000 | -13.4% | 25,300 | 0.0% | 0.08% | -16.7% | |
| UBX | New | UNITY BIOTECHNOLOGY INC | $1,024,000 | – | 296,000 | +100.0% | 0.07% | – |
| XOMA | XOMA CORP DEL | $957,000 | -4.7% | 50,809 | 0.0% | 0.07% | -8.1% | |
| ASMB | New | ASSEMBLY BIOSCIENCES INCcall | $293,000 | – | 17,800 | +100.0% | 0.02% | – |
| SVRA | Sell | SAVARA INC | $62,000 | -98.3% | 56,500 | -96.1% | 0.00% | -98.5% |
| PLRX | Exit | PLIANT THERAPEUTICS INC | $0 | – | -1,300 | -100.0% | -0.00% | – |
| EQ | Exit | EQUILLIUM INC | $0 | – | -59,014 | -100.0% | -0.01% | – |
| KLDO | Exit | KALEIDO BIOSCIENCES INC | $0 | – | -31,374 | -100.0% | -0.02% | – |
| CRVS | Exit | CORVUS PHARMACEUTICALS INC | $0 | – | -737,612 | -100.0% | -0.15% | – |
| LSACU | Exit | LIFESCI ACQUISITION CORPunit 03/31/2025 | $0 | – | -300,000 | -100.0% | -0.24% | – |
| MGTA | Exit | MAGENTA THERAPEUTICS INC | $0 | – | -450,000 | -100.0% | -0.25% | – |
| PRVL | Exit | PREVAIL THERAPEUTICS INC | $0 | – | -367,218 | -100.0% | -0.40% | – |
| EVLO | Exit | EVELO BIOSCIENCES INC | $0 | – | -1,250,000 | -100.0% | -0.45% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -135,413 | -100.0% | -0.48% | – |
| KROS | Exit | KEROS THERAPEUTICS INC | $0 | – | -220,216 | -100.0% | -0.61% | – |
| RLMD | Exit | RELMADA THERAPEUTICS INC | $0 | – | -200,000 | -100.0% | -0.66% | – |
| CRNX | Exit | CRINETICS PHARMACEUTICALS IN | $0 | – | -859,802 | -100.0% | -1.11% | – |
| FULC | Exit | FULCRUM THERAPEUTICS INC | $0 | – | -882,353 | -100.0% | -1.19% | – |
| BMYRT | Exit | BRISTOL-MYERS SQUIBB COright 99/99/9999 | $0 | – | -4,748,300 | -100.0% | -1.26% | – |
| DNLI | Exit | DENALI THERAPEUTICS INC | $0 | – | -733,561 | -100.0% | -1.31% | – |
| FATE | Exit | FATE THERAPEUTICS INC | $0 | – | -619,855 | -100.0% | -1.57% | – |
| CNST | Exit | CONSTELLATION PHARMCETICLS I | $0 | – | -837,885 | -100.0% | -1.86% | – |
| RARE | Exit | ULTRAGENYX PHARMACEUTICAL IN | $0 | – | -519,119 | -100.0% | -3.00% | – |
| DRNA | Exit | DICERNA PHARMACEUTICALS INC | $0 | – | -2,721,993 | -100.0% | -5.11% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KURA ONCOLOGY ORD | 32 | Q3 2023 | 10.5% |
| XENCOR ORD | 25 | Q3 2023 | 12.6% |
| ASSEMBLY BIOSCIENCES ORD | 23 | Q3 2020 | 19.0% |
| FIBROGEN ORD | 22 | Q1 2020 | 12.4% |
| PROTHENA ORD | 20 | Q3 2023 | 28.0% |
| IRONWOOD PHARMA CL A ORD | 20 | Q1 2020 | 13.9% |
| GALAPAGOS NV SPON ADR | 19 | Q3 2023 | 12.0% |
| MORPHIC HOLDING ORD | 18 | Q3 2023 | 8.5% |
| ARCUS BIOSCIENCES ORD | 17 | Q1 2022 | 7.1% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 8.3% |
View EcoR1 Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Mersana Therapeutics, Inc. | July 27, 2023 | 19,364,688 | 16.9% |
| TScan Therapeutics, Inc. | June 05, 2023 | 5,000,000 | 11.7% |
| 2seventy bio, Inc. | February 14, 2023 | 1,143,494 | 3.0% |
| Avidity Biosciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Surface Oncology, Inc. | February 13, 2023 | 3,924,713 | 6.5% |
| Akouos, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Alector, Inc. | February 10, 2023 | 4,056,548 | 4.9% |
| Arcus Biosciences, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Gritstone bio, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Ovid Therapeutics Inc. | February 10, 2023 | 6,117,400 | 8.7% |
View EcoR1 Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-08 |
| 3 | 2024-03-26 |
| SC 13G/A | 2024-03-26 |
| SC 13G | 2024-03-11 |
| SC 13D | 2024-02-22 |
| SC 13G | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View EcoR1 Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.